The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than $2.5 million per quarter. This data-driven, fact-based tracker will continually update based on new filings so that readers can stay up to date. Companies must file with the SEC or SEDAR to be considered for inclusion.
Fifteen companies currently qualify for inclusion, with six filing in U.S dollars and nine in the Canadian currency. In the United States,Kush Bottles (OTC: KSHB) reported FY18-Q1 (the quarter ending 11/30/17) sales of $8.85 million, which represented growth of 258%. We have updated the Canadian list to reflect the recent results from CanniMed Therapeutics (TSX: CMED) (OTC: CMMDF), which reported sales of C$4.82 million for its FY17-Q4 ending 10/31/17, a 52% increase over the same quarter a year ago, and Namaste Technologies (CSE: N) (OTC: NXTTF), which reported sales of C$4.93 million for its FY18-Q1 ending 11/30/17), a 136% increase from the same quarter a year ago.
By mid-February, Aurora Cannabis, Canopy Growth (TSX: WEED) (OTC: TWMJF), GW Pharma (NASDAQ: GWPH) and MedReleaf (TSX: LEAF) (OTC: MEDFF) will report results for the quarter ending 12/31. GW Pharma has scheduled a call for February 5th after the close, while MedReleaf and Canopy Growth will host calls on February 13th and 14th, respectively.
Visit the Public Cannabis Company Revenue Tracker to see the complete list of qualifying companies.
Get ahead of the crowd by signing up for 420 Investor when it becomes available again. It’s the largest & most comprehensive premium service for cannabis investors since 2013.